[HTML][HTML] Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
…, K Reynolds, I Scott, MW Seif, A Sharma, N Singh… - The Lancet, 2016 - thelancet.com
Background Ovarian cancer has a poor prognosis, with just 40% of patients surviving 5
years. We designed this trial to establish the effect of early detection by screening on ovarian …
years. We designed this trial to establish the effect of early detection by screening on ovarian …
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised …
U Menon, A Gentry-Maharaj, M Burnell, N Singh… - The Lancet, 2021 - thelancet.com
Background Ovarian cancer continues to have a poor prognosis with the majority of women
diagnosed with advanced disease. Therefore, we undertook the UK Collaborative Trial of …
diagnosed with advanced disease. Therefore, we undertook the UK Collaborative Trial of …
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the …
…, A Mcguire, S Campbell, L Fallowfield, N Singh… - The lancet …, 2009 - thelancet.com
Background Ovarian cancer has a high case–fatality ratio, with most women not diagnosed
until the disease is in its advanced stages. The United Kingdom Collaborative Trial of …
until the disease is in its advanced stages. The United Kingdom Collaborative Trial of …
Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy
…, HJ Mackay, A Leary, HW Nijman, N Singh… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …
p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies
N Singh, AM Piskorz, T Bosse… - The Journal of …, 2020 - Wiley Online Library
TP53 mutations are considered a surrogate biomarker of the serous‐like ‘copy number high’
molecular subtype of endometrial carcinoma (EC). In ovarian carcinoma, p53 …
molecular subtype of endometrial carcinoma (EC). In ovarian carcinoma, p53 …
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label …
…, C Hanzen, LCHW Lutgens, VT Smit, N Singh… - The lancet …, 2018 - thelancet.com
Background Although women with endometrial cancer generally have a favourable prognosis,
those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 …
those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 …
Interleukin-6 as a therapeutic target in human ovarian cancer
…, T Schioppa, J Nemeth, J Vermeulen, N Singh… - Clinical cancer …, 2011 - AACR
Purpose: We investigated whether inhibition of interleukin 6 (IL-6) has therapeutic activity in
ovarian cancer via abrogation of a tumor-promoting cytokine network. Experimental Design: …
ovarian cancer via abrogation of a tumor-promoting cytokine network. Experimental Design: …
[HTML][HTML] Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade)
N Singh, L Hirschowitz, R Zaino… - International Journal …, 2019 - journals.lww.com
Although endometrial carcinoma (EC) is generally considered to have a good prognosis,
over 20% of women with EC die of their disease, with a projected increase in both incidence …
over 20% of women with EC die of their disease, with a projected increase in both incidence …
Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical …
…, MG Harisinghani, SA Babar, N Singh… - Journal of clinical …, 2005 - ascopubs.org
Purpose Lymph node metastases affect management and prognosis of patients with gynecologic
malignancies. Preoperative nodal assessment with computed tomography or magnetic …
malignancies. Preoperative nodal assessment with computed tomography or magnetic …
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival …
…, C Hanzen, RF Kruitwagen, VT Smit, N Singh… - The lancet …, 2019 - thelancet.com
Background The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy
and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial …
and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial …
